Ani Pharmaceuticals Inc SEC filings ANIP
Ani Pharmaceuticals Inc has 1,002 filings in SEC EDGAR's recent list, going back to Nov 3, 2014. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 9, 2026 | — |
| DEF 14A | Proxy statement | Apr 9, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | May 8, 2025 | — |
| DEFA14A | Additional proxy material | Apr 10, 2025 | — |
| DEF 14A | Proxy statement | Apr 10, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 5, 2024 | — |
| DEF 14A | Proxy statement | Apr 5, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 8, 2023 | — |
| DEFA14A | Additional proxy material | Apr 11, 2023 | — |
| DEF 14A | Proxy statement | Apr 11, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2022 | — |
| DEF 14A | Proxy statement | Mar 25, 2022 | Apr 27, 2022 |
| DEFA14A | Additional proxy material | May 7, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 2, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2021 | Apr 19, 2021 |
| DEFA14A | Additional proxy material | Mar 9, 2021 | — |
| DEFA14A | Additional proxy material | Mar 9, 2021 | — |
| DEFA14A | Additional proxy material | May 21, 2020 | — |
| DEFA14A | Additional proxy material | Apr 30, 2020 | — |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 5, 2020 |
| DEFA14A | Additional proxy material | Apr 4, 2019 | — |
| DEF 14A | Proxy statement | Apr 4, 2019 | May 14, 2019 |
| DEF 14A | Proxy statement | Apr 6, 2018 | May 17, 2018 |
| DEF 14A | Proxy statement | Apr 6, 2017 | May 17, 2017 |
| DEF 14A | Proxy statement | Apr 14, 2016 | May 25, 2016 |
| DEF 14A | Proxy statement | Apr 24, 2015 | Jun 3, 2015 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANIP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1023024
- Former names
- BIOSANTE PHARMACEUTICALS INC (until Jul 18, 2013); BEN ABRAHAM TECHNOLOGIES INC (until Dec 23, 1999)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.